Renfeng Guo
Founder at INFLARX N.V.
Net worth: 2 M $ as of 2024-04-29
Renfeng Guo active positions
Companies | Position | Start | End |
---|---|---|---|
INFLARX N.V. | Director/Board Member | 2007-11-30 | - |
Chief Tech/Sci/R&D Officer | 2007-11-30 | - | |
Founder | 2007-11-30 | - |
Career history of Renfeng Guo
Former positions of Renfeng Guo
Companies | Position | Start | End |
---|---|---|---|
University of Michigan | Corporate Officer/Principal | 2000-12-31 | - |
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Director/Board Member | - | - |
Chief Tech/Sci/R&D Officer | 2007-12-10 | - | |
Founder | 2009-11-24 | - |
Training of Renfeng Guo
Norman Bethune Medical University | Doctorate Degree |
Statistics
International
Germany | 3 |
China | 2 |
United States | 2 |
Operational
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
INFLARX N.V. | Health Technology |
Private companies | 1 |
---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
- Stock Market
- Insiders
- Renfeng Guo
- Experience